1,031
Views
6
CrossRef citations to date
0
Altmetric
Letter

A hemodialysis patient with higher-risk myelodysplastic syndrome treated with standard-dose azacitidine

, &
Pages 2521-2522 | Received 18 Feb 2012, Accepted 19 Apr 2012, Published online: 21 May 2012

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Taro Edahiro, Hiroshi Ureshino, Ren Chishaki, Keita Fujino, Tatsuji Mino, Tetsumi Yoshida, Noriyasu Fukushima & Tatsuo Ichinohe. (2022) Successful combination treatment with azacitidine and venetoclax for a patient with acute myeloid leukemia undergoing hemodialysis. Leukemia & Lymphoma 63:14, pages 3511-3512.
Read now
A. G. E Beer, E. Laille, H. Neuwirt, G. Mayer & R. Stauder. (2021) Azacitidine is removed effectively by hemodialysis. Leukemia & Lymphoma 62:3, pages 743-745.
Read now

Articles from other publishers (4)

Yuina Akagi, Yusuke Yamashita, Hideki Kosako, Yoshiaki Furuya, Hiroki Hosoi, Toshiki Mushino, Shogo Murata, Akinori Nishikawa, Shinobu Tamura, Taisei Nakao & Takashi Sonoki. (2023) Administration of combined venetoclax and azacitidine in a patient with acute myeloid leukemia and multiple comorbidities undergoing dialysis: A case report. eJHaem 4:3, pages 841-843.
Crossref
Nina Rosa Neuendorff, Nico Gagelmann, Surbhi Singhal, Shelby Meckstroth, Vincent Thibaud, Yue Zhao, Nabiel Mir, Yung-Yu Shih, Danielle M.C. Amaro, Mukul Roy, Joseph Lombardo, Lars Klingen Gjærde & Kah Poh Loh. (2023) Hypomethylating agent-based therapies in older adults with acute myeloid leukemia – A joint review by the Young International Society of Geriatric Oncology and European Society for Blood and Marrow Transplantation Trainee Committee. Journal of Geriatric Oncology 14:3, pages 101406.
Crossref
SABINE KARAM, VICTORIA GUTGARTS & ILYA GLEZERMAN. 2020. Onco-Nephrology. Onco-Nephrology 183 196.e7 .
Valeria Santini & Gert J. Ossenkoppele. (2019) Hypomethylating agents in the treatment of acute myeloid leukemia: A guide to optimal use. Critical Reviews in Oncology/Hematology 140, pages 1-7.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.